The Battle of the COVID Variants: A Winning Approach

Tracking COVID Variants

Understanding why one SARS-CoV-2 variant prevails over another is crucial. A study comparing the spread and transmission of different emerging variants in parallel has provided important answers.

An international team conducted a study to understand why certain SARS-CoV-2 variants, like alpha and beta, outcompete others.

They used a variety of experimental models to simulate natural competitive conditions, discovering that while the alpha variant tends to dominate and spread more effectively, especially in the upper respiratory tract, the beta variant does not perform as well and seems to have spread due to specific epidemiological situations.

As new SARS-CoV-2 variants continue to emerge and drive the pandemic, the Institute of Virology and Immunology (IVI) and the University of Bern with international collaborators have studied emerging variants in animal (in vivo) and biophysical interaction and cell culture (in vitro) models. The originality of this new study is to have put the variants in direct competition in multiple models to reveal why some variants had a real advantage to spread globally.

According to Charaf Benarafa, senior author of the study: “Taken independently, each of the variants appears to be as effective as their progenitor, the initial virus: it is difficult to separate them. By recreating the natural conditions of competition, where an emerging variant and its progenitor are simultaneously present, it becomes possible to truly detect which variant will preferentially propagate and be transmitted to another individual. The challenge of our study was to associate different experimental models to better understand these mechanisms; and the combined analyses enabled us to discriminate the differences between the variants.”

Alpha wins in restrictive models, while beta is the “big loser”

The competition between the alpha and beta variants and their progenitor clearly shows that the alpha variant has an advantage. Charaf Benarafa explains: “The more restrictive models of virus competition showed us that the alpha variant dominates and spreads better in the upper respiratory tract and transmits more efficiently. All the models also showed that the beta variant is the “big loser.” It seems that the beta variant has benefited from favorable epidemiological circumstances to develop locally. On the other hand, the alpha variant, which has spread globally, has demonstrated its intrinsic high transmission potential through its spike mutations.

Meanwhile, Other Variants Are Emerging

Predicting which variant will better spread and why continues to be a challenge. Only in-depth studies can provide a better understanding of the factors associated with this spread. According to Charaf Benarafa, “It is with a combination of different in vitro and in vivo models that we were able to consolidate our results to explain the dominance of the alpha variant in immunologically naive populations. Now that a significant proportion of the population is vaccinated, we will also have to consider the impact of immunity on the advantage of new emerging mutants.”

Reference: “Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta” by Lorenz Ulrich, Nico Joel Halwe, Adriano Taddeo, Nadine Ebert, Jacob Schön, Christelle Devisme, Bettina Salome Trüeb, Bernd Hoffmann, Manon Wider, Xiaoyu Fan, Meriem Bekliz, Manel Essaidi-Laziosi, Marie Luisa Schmidt, Daniela Niemeyer, Victor Max Corman, Anna Kraft, Aurélie Godel, Laura Laloli, Jenna N. Kelly, Brenda M. Calderon, Angele Breithaupt, Claudia Wylezich, Inês Berenguer Veiga, Mitra Gultom, Sarah Osman, Bin Zhou, Kenneth Adea, Benjamin Meyer, Christiane Eberhardt, Lisa Thomann, Monika Gsell, Fabien Labroussaa, Jörg Jores, Artur Summerfield, Christian Drosten, Isabella Anne Eckerle, David E. Wentworth, Ronald Dijkman, Donata Hoffmann, Volker Thiel, Martin Beer and Charaf Benarafa, 22 December 2021, Nature.
DOI: 10.1038/s41586-021-04342-0

2 Comments on "The Battle of the COVID Variants: A Winning Approach"

  1. Howard Jeffrey Bender, Ph.D. | January 9, 2022 at 11:50 am | Reply

    All of these studies are about the protein spike. All the coronaviruses and all their variants have different protein spikes, with Delta and Omicron having spikes that are more efficient at getting around the vaccines. But the real problem is in the virus itself, not its protein shell, and why the most dangerous (MERS, SARS, and Covid-19) are so infectious. My independent research has found multiple one-in-a-million nucleotide sequence matches between all the coronaviruses and the human genome. Those sequences are the same as some of the loops of human tRNA. Using those loops and their amino acid code matches, viruses may be able to fool the nucleus membrane in cells to allow the virus to enter and associate with the human DNA, creating more opportunities for further infection. Our immune system may be compromised and may no longer be able to stop the virus and other diseases from attacking organs throughout the body. Vaccines that attack the virus protein shells while ignoring their contents are doomed to failure from the Darwin effect, but recognizing these loops suggests a possible approach to successful coronavirus vaccines. Only the infection process is considered in my work, not the innate virulence of the virus. For more info, check out this YouTube, Coronavirus – Using Your DNA Against You.

  2. I found this comment to be very interesting.

Leave a comment

Email address is optional. If provided, your email will not be published or shared.